Open in interactive viewer → charts, metric popovers & call review

Omeros: The Launch Works. The Arithmetic Is Getting Harder.

Second full quarter of YARTEMLEA, second quarter of positive operating cash flow — and a gross-to-net line that is climbing faster than management planned.
OMER · Earnings Call · 2026-11-16

The quarter that stopped being a launch quarter

Omeros reported on 16 November and the headline numbers look like a launch that is simply working. YARTEMLEA generated $41.8 million in gross sales and $35.9 million net — up 30% and 26% sequentially in only its second full quarter on the market. Unique ordering accounts rose 49%, from 73 at 30 June to 109, out of the 175 U.S. transplant centers the field force covers. And crucially, operating cash flow was positive for a second consecutive quarter at $13.3 million, against $4.1 million in Q2. That cash line is the real change at this company. Effective net cash sat at negative $139 million as recently as mid-2025; it was positive $59 million at the last reported quarter-end and management put cash and investments at $95.3 million at 30 September. Free cash flow less stock comp flipped from minus $16 million in Q1 2026 to plus $2 million in Q2. Two years of dilution-and-burn have become a company that funds its own pipeline.

The 340B tell

Here is where it gets interesting. Gross-to-net deductions rose from 11.5% to 14% of gross sales, and management attributes the move "almost entirely" to a substantial increase in 340B program participation. They frame that as a triumph: it means the drug is migrating from the inpatient ward to the outpatient setting, where patients are less sick, dose earlier, and hospitals earn ASP-plus spreads rather than a bundled DRG. Bill Woodman's line is the cleanest articulation of the clinical logic: “Whenever you launch an acute disease, generally, you get the sickest of the sick first.” — William Woodman, Chief Commercial Officer · 2026-11-16 The problem is the arithmetic underneath the celebration. Every incremental point of 340B discount lowers the dollars Omeros actually keeps per vial shipped. And the ceiling is not far away:

I don't think that we have shared a target number there, but I think that we are approaching it more quickly than we had anticipated... somewhere in the high teens would be what we think we might be approaching at some point. But to jump from 11.5% to 14% from the prior quarter to this quarter, we see as sort of a resounding acknowledgment, recognition and of the importance of the drug.

Gregory Demopulos, Chief Executive Officer · 2026-11-16
Compare that to May, when the same question got a far more relaxed answer: “I would not expect that to be reaching the 20 percentile... we're going to remain in the teens.” — Gregory Demopulos, Chief Executive Officer · 2026-05-13 The destination is unchanged. The speed is the news. A 250-basis-point jump in one quarter, with more to come, means headline gross growth will keep outrunning net growth — 30% gross versus 26% net is the first visible instance of that gap. Watch that spread, not the gross line. There is a second, subtler signal in the keyword set: patient level data has climbed into this company's top themes. Analysts keep asking for vials per course, inpatient/outpatient splits, patient counts. Greg Demopulos keeps declining: “We haven't shared the vial split between in and outpatient. And so we won't today.” — Gregory Demopulos, Chief Executive Officer · 2026-11-16 The company sells you accounts and gross-to-net; it will not sell you units. For a launch this young that is defensible, but it caps how precisely anyone can model the fourth quarter.

Europe goes dark; Novo and the pipeline carry the optionality

The other genuine change this quarter is subtraction. CHMP, after reexamination, issued a negative opinion on narsoplimab in TA-TMA, and Omeros is closing its compassionate-use program to new patients after ten years of free drug. Rewind to April, when the tone was very different: “We are really sort of laser-focused on achieving that approval.” — Gregory Demopulos, Chief Executive Officer · 2026-04-01 That door is now shut, and management has re-pointed regulatory effort at "countries whose regulatory bodies recognize and can build upon the drug's FDA approval." Meanwhile the reimbursement machinery in the U.S. is where the advantage now lives: an NTAP worth up to $287,000 per eligible Medicare inpatient case from 1 October, and pass-through status through June 2029 that exempts YARTEMLEA from the CMS rule cutting 340B-acquired drug reimbursement to ASP-minus-28% starting January 2027. That is a live, dated reimbursement advantage over branded eculizumab and ravulizumab — which is why the committee approvals count now stands at 80% of the top 40 centers. The offsetting spend is visible in the field-force build: ten education positions added in six weeks, a six-nurse nurse educator team drawn from top transplant centers, and a new Nephrology Speaker Bureau to reach the physicians who actually manage the kidney injury that defines this disease. That flows through to the P&L: management guided Q4 R&D and SG&A both higher. R&D as a share of revenue has already fallen sharply from the pre-launch burn years, and even a guided step-up keeps it far below historical levels. Novo's $100 million near-term milestones and $1.8 billion-plus in development and commercial payments remain the backstop.

The guidance that isn't

Here is the tension worth flagging. In August, management was explicit: “by mid 27, we expect to be cash flow positive company wide.” — Gregory A. Demopulos, CEO or President · 2026-08-12 That promise has already been beaten — twice. And yet, asked directly for 2027 guidance, the answer is deferral:

We will begin providing guidance at some point in 2027, I expect. We just want to get a sense of how the overall sales are looking. We're very pleased with what we're seeing. But what we don't want to do is get out ahead of ourselves and guide when we really don't have the data to back up that.

Gregory Demopulos, Chief Executive Officer · 2026-11-16
That is a company outperforming its own stated timeline while refusing to quantify the next one. It is also a change in register from August, when the language was about "scratching the surface" and the 56% incidence figure from the Midas studies — i.e. a total-addressable-market argument. This call barely mentions diagnosis rates. It is about throughput: outpatient conversion, NTAP education, P&T capture. The bull case has quietly shifted from more patients exist than you think to we can monetize the patients we already have more efficiently. The first is a story; the second is a spreadsheet. Spreadsheets are harder to sell.

The tape and the rhyme

The stock has already voted and then un-voted. Over 90 days OMER is up 32.6%, having doubled into a 22 September peak of $21.05 before giving back a third — a 33.9% drawdown from that high into the print. The full history sits at a 47.8% drawdown from the 2018 peak of $26.69. At roughly $1 billion of market cap and price to revenue near 17.8x, none of this is cheap. And the comparison every analyst wants to make, Steve Brozak finally made: Alexion. Demopulos did not dodge it — “for third quarter of their sales versus third quarter of our sales, our sales U.S. only, we exceed their third quarter worldwide sales” — Gregory Demopulos, Chief Executive Officer · 2026-11-16 — while correctly noting the structural difference between a chronic PNH franchise and an acute, episodic course. It is a genuine compliment to the launch. It is also a reminder that the market is pricing YARTEMLEA against a compound that became a $40-billion-company, not against a $1-billion one. Where does that leave the story? Cleanly bifurcated. Half of it is a commercial launch that is beating its own plan, funding itself, and shrinking its share count. The other half is a financial instruments footnote — a $62 million noncash mark-to-market loss on the 2029 convertibles that turned a $4.7 million adjusted profit into a $57.4 million GAAP loss and will keep doing so until the remaining $40.3 million of paper is retired. Two quarters of note repurchases have already cut the principal 43% and the dilution by 5.8 million shares this year. As Demopulos put it, “As soon as we get rid of the convert overhang... that derivative will disappear with it.” — Gregory Demopulos, Chief Executive Officer · 2026-11-16 Until then, the GAAP line will keep lying in both directions. The operating line, for the first time in this company's public life, is not.